EMA considering Novartis biosimilar of Pfizer's Enbrel; Which 5 pharma companies are 'happiest' places to work?;

@FiercePharma: Japan's Kaketsuken at center of major vaccine, blood product records fraud. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: J&J, AbbVie's Imbruvica builds on case for first-line CLL use at ASH. More | Follow @CarlyHFierce

> India's Cipla has reorganized its top ranks again. Story

> Novartis' ($NVS) Sandoz unit has had its application for a biosimilar of Pfizer's ($PFE) blockbuster Enbrel accepted by the European Medicines Agency after earlier submitting it to the FDA. Release

> Amgen ($AMGN), Novartis, Johnson & Johnson ($JNJ), Merck & Co. ($MRK) and Pfizer have all placed in the top 50 happiest places to work in the U.S., ranked by CareerBliss. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: AstraZeneca, NCI tap French company to develop companion mobile app for cancer drugs. Article | Follow @FierceMedDev

@EmilyWFierce: Google Life Sciences will now be known as "Verily." More | Follow @EmilyWFierce

> FDA gives nod for mini-sponge, gunshot wound dressing device for civilians. Story

> Upstart wins CE mark for first swallowable weight-loss gastric balloon. Article

Biotech News

@FierceBiotech: Busy Roche inks another immuno-oncology discovery pact, this time with Pieris. News | Follow @FierceBiotech

@JohnCFierce: In the category of 'can't make this stuff up,' $NWBO issued a followup statement saying why Leary wouldn't work. More | Follow @JohnCFierce

> Pfizer bets up to $1B on BioAtla's approach to immuno-oncology. More

> Alexion grabs an FDA OK--the 41st of '15--for rare-disease drug Kanuma. News

> Sitting on $25B, Gilead goes shopping for high-dollar buyouts. Article

Drug Delivery News

> 'Smart' hydrogel wound dressing delivers drugs from reservoirs. News

> FDA funds computer simulations in bid to speed up development of long-acting generics. Story

> Clearside closes $20M round for candidates that are injected into the eye's suprachoroidal space. More

> University of Warwick spinout develops first transdermal ibuprofen pain patch. Report

> Metal 'nano-terminator' liquefies on demand to bring cancer down. Article

Pharma Manufacturing News

> FDA gives Sun Pharma go-ahead to manufacture generic version of cancer drug Gleevec. Item

> Associated Press: Taxpayers' tally to entice Novo Nordisk to NC may top $130M. More

> South African health activists protest Sanofi over lack of BCG vaccine. Article

> Catalent production issues at French plant cause delay in GSK launch. Story

> AstraZeneca shuttering Bengaluru, India API plant, citing low demand. Report

Pharma Asia News

> China economy not the main culprit in pharma slowdown, FT says. Article

> Outlook for early 2016 in Asia sees headwinds for Japan, India and Thailand. Report

> Japan's Kaketsuken at center of major vaccine, blood product records fraud. More

> China superbug has already gone global, Danish researcher says. Story

> India a potential center for orphan drug development and demand. Article

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.